News
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted For Presentation At The 2024 ASCO Annual Meeting
24 Apr 24
Biotech, News, General
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules As Potential Therapy For Inflammatory Bowel Disease At AAI Annual Meeting
23 Apr 24
Biotech, News, Events, General
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects Of Pro-Inflammatory Cytokine Therapeutics WTX-518 And WTX-712 At AACR 2024 Annual Meeting
5 Apr 24
Biotech, News, General
JMP Securities Initiates Coverage On Werewolf Therapeutics with Market Outperform Rating, Announces Price Target of $12
3 Apr 24
News, Price Target, Initiation, Analyst Ratings
HC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Maintains $15 Price Target
7 Mar 24
News, Price Target, Analyst Ratings
Recap: Werewolf Therapeutics Q4 Earnings
7 Mar 24
Earnings
Werewolf Therapeutics Q4 EPS $(0.33) Beats $(0.43) Estimate, Sales $1.50M Miss $1.94M Estimate
7 Mar 24
Earnings, News
Press releases
Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting
5 Apr 24
News, Health Care, Press Releases
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
4 Apr 24
News, Press Releases
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7 Mar 24
Earnings, Press Releases